Antipsychotic Treatment of Schizophrenia & Mood Disorders
Company Founded Year
Company Number of Employees
Mental-Heal by Abital, is developing a novel oral antipsychotic drug, PGW-5, for the treatment of Schizophrenia and Bipolar disorder. PGW-5 is a novel neuroleptic, multi-target agent which is potentially effective for the treatment of the Positive and Negative Symptoms of Schizophrenia as well as, for Cognitive Deficits and Mood Disorder. The possible mechanisms underlying the differential effects of the drugs may involve the brain glutamate NMDA (N-Methyl-D-Aspartate receptor) system as well as neurotrophic factors and food intake regulating peptides. Early scientific work in animal models has shown that PGW-5 has anxiolytic and antidepressant activity and improvement of impaired social performance in PCP treated mice.